PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trials

19 recruiting

PDAC - Pancreatic Ductal Adenocarcinoma Trials at a Glance

19 actively recruiting trials for pdac - pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Boston, New York, and Fairfax. Lead sponsors running pdac - pancreatic ductal adenocarcinoma studies include Azienda Ospedaliera Universitaria Integrata Verona, Imperial College London, and Revolution Medicines, Inc..

Browse pdac - pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PDAC - Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PDAC - Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Not Applicable

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

PDAC - Pancreatic Ductal Adenocarcinoma
Massachusetts General Hospital50 enrolled1 locationNCT07047807
Recruiting
Not Applicable

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

PDAC - Pancreatic Ductal Adenocarcinoma
IHU Strasbourg60 enrolled2 locationsNCT06666803
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.188 enrolled10 locationsNCT06835569
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma

Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London1,005 enrolled1 locationNCT05727020
Recruiting

Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)

Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London6,079 enrolled1 locationNCT07243262
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Gastric AdenocarcinomaGEJ AdenocarcinomaPDAC - Pancreatic Ductal Adenocarcinoma+4 more
Avacta Life Sciences Ltd144 enrolled2 locationsNCT07454642
Recruiting

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Pancreatic CancerPancreatic Ductal AdenocarcinomaPDAC+1 more
Mayo Clinic5,000 enrolled1 locationNCT06151223
Recruiting
Phase 1

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 4

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Neuro Endocrine TumoursPDAC - Pancreatic Ductal AdenocarcinomaPancreas Adenocarcinoma+7 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)400 enrolled1 locationNCT07262957
Recruiting
Not Applicable

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaHyperglycemia
British Columbia Cancer Agency50 enrolled2 locationsNCT05132244
Recruiting

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaIntraductal Papillary Mucinous Neoplasm+2 more
Changhai Hospital400,000 enrolled5 locationsNCT07117045
Recruiting
Early Phase 1

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Pancreatic CancerPancreatic Ductal AdenocarcinomaPDAC+2 more
Dana-Farber Cancer Institute5,000 enrolled2 locationsNCT06122896
Recruiting
Phase 1Phase 2

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic CancerPancreas CancerPancreatic Neoplasms+1 more
Chinese PLA General Hospital90 enrolled1 locationNCT05218889
Recruiting
Not Applicable

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability

PDAC - Pancreatic Ductal Adenocarcinoma
Azienda Ospedaliera Universitaria Integrata Verona165 enrolled1 locationNCT05853198
Recruiting

Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

PDAC - Pancreatic Ductal Adenocarcinoma
Azienda Ospedaliera Universitaria Integrata Verona3,000 enrolled1 locationNCT05845801